ClinicaliQ Trial Snapshot
- A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide — Active Not Recruiting • Oncology • NCT05901649.
- Real-world comparison of apalutamide versus enzalutamide, both combined with standard hormone therapy, in men with advanced prostate cancer.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to assess the real-world outcomes differences between apalutamide or enzalutamide plus androgen deprivation therapy (ADT) for the treatment of participants with metastatic hormone-sensitive prostate cancer (mHSPC). Conditions: Metastatic Hormone-sensitive Prostate Cancer Interventions: Apalutamide, Enzalutamide Lead Sponsor: Janssen-Cilag Ltd. Planned Enrollment: 504 participants